OR WAIT 15 SECS
Volume 40, Issue 5
Welcome to the new look and branding of Pharmaceutical Executive-reimagined to better reflect you, our audience, and expand on the content you've long trusted us to deliver.
After a short hiatus, the Pharmaceutical Executive Emerging Pharma Leaders recognition reemerges in this issue. The Class of 2020 features 11 leaders who span large pharma to emerging biotech, as well as roles that lead the various complex and innovative areas across their respective companies. We started the Emerging
Pharma Leaders (EPLs) nomination and voting process well before the pandemic and conducted interviews on the cusp of the initial lockdowns. Therefore, we
didn’t discuss COVID-specific questions. However, we can clearly see how leadership determines the path biopharma companies navigate through not only a very complex and regulated industry, but how leaders can steer through public and global crises.
One of the criteria the judges used to evaluate our EPLs is the actions that nominees took to ensure their path in the C-suite. That determination speaks not only to the desire to lead, but the qualities needed to guide biopharma through difficult times.
Everyone here at Pharmaceutical Executive is extremely excited to debut the EPLs milestone with another, the
, one which was a true collaboration between many departments and our external Editorial Advisory Board. You may have noticed that we also changed the tagline of Pharmaceutical Executive to “Master the Science of Success.” Though we have had a few taglines in the brand’s existence, this one speaks eloquently to you, the audience, and reiterates what we provide you from reading our articles in print or on the web, or engaging with our other media platforms such as enewsletters or webcasts, eBooks or videos, podcasts or virtual events. We are dedicated to providing you with the information and tools you need to lead and succeed in this industry.
We’ve reimagined the design of the publication to better reflect our audience, as well as the pacing of the articles, so that you know where to find your favorite columns, or easily page to the Executive Profiles or in-depth features. Thank you to our exceptional design staff, Jeff Brown, Ray Pelesko, Marie Maresco, and Maya Hariharan for their talent in transforming our thoughts into a tangible vision.
To our regular columnists who have provided exceptional coverage of the FDA and EU regulatory and government landscapes, we’ve added four more regular staples. The Financial column is authored by Barbara Ryan, an EAB member and founder of Barbara Ryan Advisors, a capital markets and communications firm she started in 2012 following more than 30 years on Wall Street as a sell-side research analyst covering the US Large Cap Pharmaceutical Industry. Her opinions and expertise are widely sought; she is frequently quoted in the press and appears on CNBC; and she is well-positioned to provide our readers with with the insights and current financial outlook for biopharma.
Sandor Schoichet is well-placed to pen our new Biopharma Sustainability column. In his capacity as Director & Independent Advisor, Meridian Management Consultants, he co-founded the Biopharma Sustainability Roundtable, an annual invitation-only Roundtable and Investor Day. Topics have included sustainability strategy, program management, and enterprise process improvement. Sandor has worked with several life science, IT, and technology development organizations in executive and consulting roles.
Our Technology column is helmed by Julian Upton, Pharmaceutical Executive’s European and Online Editor. Often writing on the topic already, our go-to tech expert will continue to provide the right balance of know-how with ways companies evaluate success.
Elaine Quilici, our Senior Editor, will contribute a monthly column on Leadership. In the past year, Elaine has taken charge of the PharmExec podcast, as well as writing features and executive profiles. Leadership takes many forms, so this column will be diverse, and it will address, again, the success strategies you can consider for you and your organization.
As we move forward with our new design and our new “Master the Science of Success” as our compass, we will continue to bring you the content you’ve grown to rely on. COVID-19 has impacted many biopharma companies in the short-term, and will continue into the long-term. Our articles will continue to weave lessons learned from the biopharma community as we move onto the next stages of the pandemic. June’s annual Pharma 50 issue will also include an article on how large pharma responded to the crisis. Moving into September, the annual Brand Launch issue will tackle how brands were affected overall by the pandemic, whether sales, marketing pivots, or patient access. With Science part of the Success equation, our November Pipeline issue will offer a COVID therapy development section, at which time the landscape will have hopefully dramatically changed.
Please enjoy our new design and branding, and please share your opinions with us.
Lisa Henderson is Editor-in-Chief of Pharm Exec. She can be reached at firstname.lastname@example.org. Follow Lisa on Twitter: @trialsonline